Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript

Sangamo Therapeutics reported significant Q2 2025 pipeline advancements, highlighted by positive top-line results from its registrational STAAR study for ST-920 in Fabry disease; the FDA has agreed to use the positive 1-year eGFR slope as the primary basis for accelerated approval, with a BLA submission targeted for Q1 2026. The company also became a clinical-stage neurology genomic medicine company with the initiation of the Phase 1/2 STAND study for ST-503 in chronic neuropathic pain, anticipating first patient dosing this fall and preliminary efficacy data by Q4 2026, while progressing ST-506 for prion disease towards a mid-2026 CTA submission. Financially, Sangamo's cash runway extends into Q4 2025, underscoring the critical need for a near-term Fabry commercialization agreement to secure long-term funding and advance its promising pipeline.

Analysis

Sangamo Therapeutics presented a compelling clinical update alongside a precarious financial position in its Q2 2025 earnings call. The highlight is the positive top-line data from the registrational STAAR study for its Fabry disease gene therapy, ST-920. The therapy achieved a positive mean annualized eGFR slope of nearly 2 at 52 weeks across 32 patients, a remarkable outcome given that untreated patients typically see a decline of -3 to -4. This result serves as the primary basis for a planned BLA submission under the FDA's accelerated approval pathway as early as Q1 2026. Supporting data showed durable efficacy, with a positive eGFR slope of 1.7 at two years for 19 patients, stabilization of cardiac endpoints, and significant quality-of-life improvements. The company also advanced its neurology pipeline, initiating a Phase 1/2 study for its chronic pain candidate, ST-503, positioning itself as a clinical-stage neurology company with initial data anticipated in Q4 2026. However, this clinical progress is set against a significant financial overhang; the company's cash runway is only expected to last into Q4 2025. Management has explicitly identified securing a near-term commercialization partner for the Fabry program as a critical priority to solve its long-term funding needs, making the outcome of these ongoing negotiations the most pivotal near-term catalyst.

Key Decisions for Investors

• The investment thesis for SGMO is dominated by the binary outcome of securing a commercialization partner for its Fabry disease program (ST-920); investors should closely monitor for partnership announcements as this is critical to resolving the company's funding runway, which currently extends only to Q4 2025.
• Given the positive registrational data and clear regulatory path for ST-920, a successful partnership could significantly de-risk the company and lead to a substantial stock re-rating, while failure or significant delay poses a material liquidity risk.
• Pay close attention to the detailed ST-920 data presentation at the ICIEM conference in September 2025, as a strong reception could enhance Sangamo's negotiating leverage with potential partners and reinforce confidence ahead of the planned Q1 2026 BLA submission.
• While the neurology pipeline, particularly the newly initiated ST-503 pain study, offers long-term potential, its value is currently suppressed by the near-term financial uncertainty and should be considered a secondary value driver pending resolution of the funding gap.